E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Ali Mortazavi |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Chairman |
|
b) |
Initial notification/ Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
e-therapeutics plc |
|
b) |
LEI |
21380049RHSSJXWKYT18 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
|
b) |
Nature of the transaction |
Purchase of new shares as part of a placing
|
|
c) |
Price(s) and volume(s) |
1,666,666 ordinary shares at a price of 12 pence per share |
|
d) |
Aggregated information - Aggregated volume - Price
|
N/A |
|
e) |
Date of the transaction |
15 July 2020 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Michael Bretherton |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Non-Executive Director |
|
b) |
Initial notification/ Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
e-therapeutics plc |
|
b) |
LEI |
21380049RHSSJXWKYT18 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
|
b) |
Nature of the transaction |
Purchase of new shares as part of a placing |
|
c) |
Price(s) and volume(s) |
500,000 ordinary shares at a price of 12 pence per share |
|
d) |
Aggregated information - Aggregated volume - Price
|
N/A |
|
e) |
Date of the transaction |
15 July 2020 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Trevor Jones |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Non-Executive Director |
|
b) |
Initial notification/ Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
e-therapeutics plc |
|
b) |
LEI |
21380049RHSSJXWKYT18 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
|
b) |
Nature of the transaction |
Purchase of new shares as part of a placing |
|
c) |
Price(s) and volume(s) |
50,000 ordinary shares at a price of 12 pence per share |
|
d) |
Aggregated information - Aggregated volume - Price
|
N/A |
|
e) |
Date of the transaction |
15 July 2020 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
For further information, please contact:
|
e-therapeutics plc Ali Mortazavi, Executive Chairman Laura Roca-Alonso, Chief Business Officer
|
Tel: +44 (0) 1993 883 125
|
|
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser) James Black (Corporate Broking)
|
Tel: +44 (0) 207 260 1000
|
|
FTI Consulting Simon Conway/Stephanie Cuthbert |
Tel: +44 (0) 207 727 1000 |
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
